Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension
Sponsor: Vanderbilt University
Terminated
We were not able to enroll adequate number of participants that met the inclusion/exclusion criteria, and we run out of funding.
This PHASE1 trial investigates Hypertension and Hypertension, Essential and is currently terminated or withdrawn. Vanderbilt University leads this study, which shows 15 recorded versions since 2015 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Feb 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE1
-
Mar 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 10 earlier versions
-
Jan 2022 — Mar 2022 [monthly]
Recruiting PHASE1
-
Feb 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Sep 2019 — Mar 2020 [monthly]
Recruiting PHASE1
-
Sep 2018 — Sep 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE1
Phase: NA → PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vanderbilt University
For direct contact, visit the study record on ClinicalTrials.gov .